ArticleCancer diagnosis & prognosis

First-line Enfortumab Vedotin Plus Pembrolizumab in Platinum-ineligible Advanced Urothelial Carcinoma.

G O Kaneko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.